Hereditary Angioedema Market By Drug Class (C1 Esterase Inhibitors, Kallikrien Inhibitor, Selective Bradykinin B2 Receptor Antagonist), By Product Drugs (Phase Iii Drug, Phase Ii Drug (Qualitative Information) ) - Growth, Future Prospects, And Competitive Analysis, 2017 -2025

Hereditary angioedema is a disorder that results in frequent attacks of pain and inflammation accompanied with the swelling of legs, intestinal tract, arms, face and airway tract. There are three types of hereditary angioedema, types I, II and III which are distinguished by the underlying causes and the levels of blood protein called C1 inhibitors. Phenotypic expression in hereditary angioedema varies widely even among family members, the frequency and severity of attacks are unpredictable giving an expression that similar symptoms arises in all types. Type III was initially thought to be prevalent only in women but incidences have occurred in males in the same affected families.

For the purpose of this study, the global hereditary angioedema market is studied in terms of drug classes, pipeline drugs and geography. The drug classes studied in the report include C1 esterase inhibitors (Berinert, Haegarda, Cinryze and Ruconest), kallikrein inhibitors (Kalbitor), selective bradykinin B2 receptor antagonist (Firazyr) and others. The current pipeline drugs for this market include Phase III drug DX-2930 and phase II drug BCX-7353. Market size estimates and forecast of these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

The geographic segmentation of the global hereditary angioedema market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The regions are also further sub-segmented on the basis of major countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global hereditary angioedema market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global hereditary angioedema market. The key players profiled in this report are BioCryst Pharmaceuticals, Inc., Cipla, Inc., CSL Behring Ltd., Ionis Pharmaceuticals, Inc., iBio, Inc., Merck & Co., Inc., Pharming Group NV, Sanofi N.V., Shire plc, and Teva Pharmaceutical Industries Ltd.

Hereditary Angioedema Market

Choose License Type
Published Date:  Sep 2017
Category:  Pharmaceuticals
Report ID:   58675
Report Format:   PDF
Pages:   120
Rating:    4.5 (70)
Connect With Us
+1-408-641-3282
24/7 Research Support